Expertise in
10
conditions

Laura D. Locati

Head And Neck Medical Oncology Unit, 
Milan, IT 
Expertise in
10
conditions
Head And Neck Medical Oncology Unit, 
Milan, IT 

Overview

Laura Locati practices practicing medicine in Milan, Italy.

Ms. Locati is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Salivary Gland Tumors, Adenoid Cystic Carcinoma, Thyroid Cancer, Thyroidectomy, and Liver Embolization.

She is actively involved in clinical research, co-authoring 189 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Head And Neck Medical Oncology Unit, Milan, 20133, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Bicalutamide, Triptorelin, Cisplatin, Doxorubicin, Carboplatin, Paclitaxel
Study Phase: Phase 2
Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer (sMTC) Patients and Possible Correlation With Vandetanib Therapy
Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer (sMTC) Patients and Possible Correlation With Vandetanib Therapy
Enrollment Status: Completed
Publish Date: September 30, 2021
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: September 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: August 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

189 Total Publications

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.
Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: June 24, 2026

Frequently Asked Questions about Laura D. Locati

Is Laura D. Locati a top-rated expert for Salivary Gland Tumors?

MediFind is an objective health platform that identifies experts based on real-world data. Laura D. Locati is classified as an Elite expert for Salivary Gland Tumors, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Laura D. Locati participate in research or clinical trials?

Yes. Laura D. Locati has published 189 articles and abstracts on conditions like Salivary Gland Tumors. You can view a list of Laura D. Locati's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Locati's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile